Literature DB >> 23409871

Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.

Panayiotis A Procopiou1, John W Barrett, Nicholas P Barton, Malcolm Begg, David Clapham, Royston C B Copley, Alison J Ford, Rebecca H Graves, David A Hall, Ashley P Hancock, Alan P Hill, Heather Hobbs, Simon T Hodgson, Coline Jumeaux, Yannick M L Lacroix, Afjal H Miah, Karen M L Morriss, Deborah Needham, Emma B Sheriff, Robert J Slack, Claire E Smith, Steven L Sollis, Hugo Staton.   

Abstract

A series of indazole arylsulfonamides were synthesized and examined as human CCR4 antagonists. Methoxy- or hydroxyl-containing groups were the more potent indazole C4 substituents. Only small groups were tolerated at C5, C6, or C7, with the C6 analogues being preferred. The most potent N3-substituent was 5-chlorothiophene-2-sulfonamide. N1 meta-substituted benzyl groups possessing an α-amino-3-[(methylamino)acyl]-group were the most potent N1-substituents. Strongly basic amino groups had low oral absorption in vivo. Less basic analogues, such as morpholines, had good oral absorption; however, they also had high clearance. The most potent compound with high absorption in two species was analogue 6 (GSK2239633A), which was selected for further development. Aryl sulfonamide antagonists bind to CCR4 at an intracellular allosteric site denoted site II. X-ray diffraction studies on two indazole sulfonamide fragments suggested the presence of an important intramolecular interaction in the active conformation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23409871     DOI: 10.1021/jm301572h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists.

Authors:  Nicholas Kindon; Glen Andrews; Andrew Baxter; David Cheshire; Paul Hemsley; Timothy Johnson; Yu-Zhen Liu; Dermot McGinnity; Mark McHale; Antonio Mete; James Reuberson; Bryan Roberts; John Steele; Barry Teobald; John Unitt; Deborah Vaughan; Iain Walters; Michael J Stocks
Journal:  ACS Med Chem Lett       Date:  2017-09-01       Impact factor: 4.345

2.  Structure-activity relationship study and discovery of indazole 3-carboxamides as calcium-release activated calcium channel blockers.

Authors:  Sha Bai; Masazumi Nagai; Steffi K Koerner; Aristidis Veves; Lijun Sun
Journal:  Bioorg Med Chem Lett       Date:  2016-12-27       Impact factor: 2.823

Review 3.  Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts.

Authors:  Eric A Wold; Jianping Chen; Kathryn A Cunningham; Jia Zhou
Journal:  J Med Chem       Date:  2018-08-28       Impact factor: 7.446

4.  GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014.

Authors:  Alexander Heifetz; Gebhard F X Schertler; Roland Seifert; Christopher G Tate; Patrick M Sexton; Vsevolod V Gurevich; Daniel Fourmy; Vadim Cherezov; Fiona H Marshall; R Ian Storer; Isabel Moraes; Irina G Tikhonova; Christofer S Tautermann; Peter Hunt; Tom Ceska; Simon Hodgson; Mike J Bodkin; Shweta Singh; Richard J Law; Philip C Biggin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-03-14       Impact factor: 3.000

Review 5.  Targeting chemokine receptors in disease--a case study of CCR4.

Authors:  Roberto Solari; James E Pease
Journal:  Eur J Pharmacol       Date:  2015-05-14       Impact factor: 4.432

6.  Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies.

Authors:  Martin J Scott; Amanda Jowett; Martin Orecchia; Peter Ertl; Larissa Ouro-Gnao; Julia Ticehurst; David Gower; John Yates; Katie Poulton; Carol Harris; Michael J Mullin; Kathrine J Smith; Alan P Lewis; Nick Barton; Michael L Washburn; Ruud de Wildt
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.